Modulations of protease activated receptors

US8927503B2 · kind B2 · utility

Assignee

• The University Of Queensland · AU

Inventors

• David Fairlie · Faulconbridge, AU
• Ligong Liu · Calle de la Era, AU
• Mei Kwan Yau · Brisbane, AU
• Jacky Yung Suen · Brisbane, AU
• Robert C. Reid · Calle de la Era, AU

Key dates

• Filing date: Jul 28, 2011
• Grant date: Jan 6, 2015
• Expiry date: Jul 28, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.